

United States Checkpoint Inhibitors for Treating Cancer Market Report 2017

<https://marketpublishers.com/r/U63D62B1871EN.html>

Date: November 2017

Pages: 97

Price: US\$ 3,800.00 (Single User License)

ID: U63D62B1871EN

Abstracts

In this report, the United States Checkpoint Inhibitors for Treating Cancer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of Checkpoint Inhibitors for Treating Cancer in these regions, from 2012 to 2022 (forecast).

United States Checkpoint Inhibitors for Treating Cancer market competition by top manufacturers/players, with Checkpoint Inhibitors for Treating Cancer sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top

players including

Bristol-Myers Squibb(BMS)

Merck

Roche

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

PD-1 inhibitors

PD-L1 inhibitors

CTLA-4 inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Melanoma Treatment

Bladder Cancer Treatment

Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Checkpoint Inhibitors for Treating Cancer Market Report 2017

1 CHECKPOINT INHIBITORS FOR TREATING CANCER OVERVIEW

1.1 Product Overview and Scope of Checkpoint Inhibitors for Treating Cancer

1.2 Classification of Checkpoint Inhibitors for Treating Cancer by Product Category

1.2.1 United States Checkpoint Inhibitors for Treating Cancer Market Size (Sales Volume) Comparison by Type (2012-2022)

1.2.2 United States Checkpoint Inhibitors for Treating Cancer Market Size (Sales Volume) Market Share by Type (Product Category) in 2016

1.2.3 PD-1 inhibitors

1.2.4 PD-L1 inhibitors

1.2.5 CTLA-4 inhibitors

1.3 United States Checkpoint Inhibitors for Treating Cancer Market by Application/End Users

1.3.1 United States Checkpoint Inhibitors for Treating Cancer Market Size (Consumption) and Market Share Comparison by Application (2012-2022)

1.3.2 Melanoma Treatment

1.3.3 Bladder Cancer Treatment

1.3.4 Other

1.4 United States Checkpoint Inhibitors for Treating Cancer Market by Region

1.4.1 United States Checkpoint Inhibitors for Treating Cancer Market Size (Value) Comparison by Region (2012-2022)

1.4.2 The West Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)

1.4.3 Southwest Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)

1.4.4 The Middle Atlantic Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)

1.4.5 New England Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)

1.4.6 The South Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)

1.4.7 The Midwest Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)

1.5 United States Market Size (Value and Volume) of Checkpoint Inhibitors for Treating Cancer (2012-2022)

1.5.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2022)

1.5.2 United States Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2022)

2 UNITED STATES CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Market Share of Key Players/Suppliers (2012-2017)

2.2 United States Checkpoint Inhibitors for Treating Cancer Revenue and Share by Players/Suppliers (2012-2017)

2.3 United States Checkpoint Inhibitors for Treating Cancer Average Price by Players/Suppliers (2012-2017)

2.4 United States Checkpoint Inhibitors for Treating Cancer Market Competitive Situation and Trends

2.4.1 United States Checkpoint Inhibitors for Treating Cancer Market Concentration Rate

2.4.2 United States Checkpoint Inhibitors for Treating Cancer Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES CHECKPOINT INHIBITORS FOR TREATING CANCER SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Region (2012-2017)

3.2 United States Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Region (2012-2017)

3.3 United States Checkpoint Inhibitors for Treating Cancer Price by Region (2012-2017)

4 UNITED STATES CHECKPOINT INHIBITORS FOR TREATING CANCER SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type (Product Category) (2012-2017)

4.2 United States Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2012-2017)

4.3 United States Checkpoint Inhibitors for Treating Cancer Price by Type (2012-2017)

4.4 United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Type (2012-2017)

5 UNITED STATES CHECKPOINT INHIBITORS FOR TREATING CANCER SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Application (2012-2017)

5.2 United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

6 UNITED STATES CHECKPOINT INHIBITORS FOR TREATING CANCER PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Bristol-Myers Squibb(BMS)

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Merck

6.2.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 Roche

6.3.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

7 CHECKPOINT INHIBITORS FOR TREATING CANCER MANUFACTURING COST ANALYSIS

7.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Checkpoint Inhibitors for Treating Cancer Major Manufacturers in 2016

8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

11 UNITED STATES CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Checkpoint Inhibitors for Treating Cancer Sales Volume, Revenue Forecast (2017-2022)

11.2 United States Checkpoint Inhibitors for Treating Cancer Sales Volume Forecast by Type (2017-2022)

11.3 United States Checkpoint Inhibitors for Treating Cancer Sales Volume Forecast by Application (2017-2022)

11.4 United States Checkpoint Inhibitors for Treating Cancer Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Checkpoint Inhibitors for Treating Cancer

Figure United States Checkpoint Inhibitors for Treating Cancer Market Size (K Units) by Type (2012-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume Market Share by Type (Product Category) in 2016

Figure PD-1 inhibitors Product Picture

Figure PD-L1 inhibitors Product Picture

Figure CTLA-4 inhibitors Product Picture

Figure United States Checkpoint Inhibitors for Treating Cancer Market Size (K Units) by Application (2012-2022)

Figure United States Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Application in 2016

Figure Melanoma Treatment Examples

Table Key Downstream Customer in Melanoma Treatment

Figure Bladder Cancer Treatment Examples

Table Key Downstream Customer in Bladder Cancer Treatment

Figure Other Examples

Table Key Downstream Customer in Other

Figure United States Checkpoint Inhibitors for Treating Cancer Market Size (Million USD) by Region (2012-2022)

Figure The West Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)

Figure Southwest Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Middle Atlantic Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)

Figure New England Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)

Figure The South of US Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Midwest Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD)

and Growth Rate (2012-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Market Major Players Product Sales Volume (K Units) (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Sales (K Units) of Key Players/Suppliers (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Sales Share by Players/Suppliers (2012-2017)

Figure 2016 United States Checkpoint Inhibitors for Treating Cancer Sales Share by Players/Suppliers

Figure 2017 United States Checkpoint Inhibitors for Treating Cancer Sales Share by Players/Suppliers

Figure United States Checkpoint Inhibitors for Treating Cancer Market Major Players Product Revenue (Million USD) (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) by Players/Suppliers (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Players/Suppliers (2012-2017)

Figure 2016 United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Players/Suppliers

Figure 2017 United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Players/Suppliers

Table United States Market Checkpoint Inhibitors for Treating Cancer Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)

Figure United States Market Checkpoint Inhibitors for Treating Cancer Average Price (USD/Unit) of Key Players/Suppliers in 2016

Figure United States Checkpoint Inhibitors for Treating Cancer Market Share of Top 3 Players/Suppliers

Figure United States Checkpoint Inhibitors for Treating Cancer Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Checkpoint Inhibitors for Treating Cancer Product Category

Table United States Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Region (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Sales Share by Region (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Share by Region (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2016

Table United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Market Share by Region (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Region (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2016

Table United States Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) by Region (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Type (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2016

Table United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Market Share by Type (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Type (2012-2017)

Figure Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Type in 2016

Table United States Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) by Types (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Type (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Application (2012-2017)

Table United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by

Application in 2016

Table United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Application (2012-2017)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Application (2012-2017)

Table Bristol-Myers Squibb(BMS) Basic Information List

Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2012-2017)

Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Market Share in United States (2012-2017)

Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Revenue Market Share in United States (2012-2017)

Table Merck Basic Information List

Table Merck Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Merck Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2012-2017)

Figure Merck Checkpoint Inhibitors for Treating Cancer Sales Market Share in United States (2012-2017)

Figure Merck Checkpoint Inhibitors for Treating Cancer Revenue Market Share in United States (2012-2017)

Table Roche Basic Information List

Table Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Roche Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2012-2017)

Figure Roche Checkpoint Inhibitors for Treating Cancer Sales Market Share in United States (2012-2017)

Figure Roche Checkpoint Inhibitors for Treating Cancer Revenue Market Share in United States (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Checkpoint Inhibitors for Treating Cancer

Figure Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer

Figure Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis

Table Raw Materials Sources of Checkpoint Inhibitors for Treating Cancer Major Players/Suppliers in 2016

Table Major Buyers of Checkpoint Inhibitors for Treating Cancer

Table Distributors/Traders List

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) and Growth Rate Forecast (2017-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) Trend Forecast (2017-2022)

Table United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) Forecast by Type (2017-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) Forecast by Type (2017-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) Forecast by Type in 2022

Table United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) Forecast by Application (2017-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) Forecast by Application (2017-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) Forecast by Application in 2022

Table United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) Forecast by Region (2017-2022)

Table United States Checkpoint Inhibitors for Treating Cancer Sales Volume Share Forecast by Region (2017-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume Share Forecast by Region (2017-2022)

Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume Share Forecast by Region in 2022

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

I would like to order

Product name: United States Checkpoint Inhibitors for Treating Cancer Market Report 2017

Product link: <https://marketpublishers.com/r/U63D62B1871EN.html>

Price: US\$ 3,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U63D62B1871EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970